{"nctId":"NCT00609492","briefTitle":"Evaluate Safety and Immunogenicity of a Booster Dose of Pneumococcal Conjugate Vaccine in Preterm Born Infants.","startDateStruct":{"date":"2008-01-03","type":"ACTUAL"},"conditions":["Infections, Streptococcal","Streptococcus Pneumoniae Vaccines"],"count":245,"armGroups":[{"label":"Preterm I Group","type":"EXPERIMENTAL","interventionNames":["Biological: GSK Biologicals´ Pneumococcal Conjugate Vaccine (GSK1024850A)","Biological: Infanrix™-IPV/Hib"]},{"label":"Preterm II Group","type":"EXPERIMENTAL","interventionNames":["Biological: GSK Biologicals´ Pneumococcal Conjugate Vaccine (GSK1024850A)","Biological: Infanrix™-IPV/Hib"]},{"label":"Full term Group","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: GSK Biologicals´ Pneumococcal Conjugate Vaccine (GSK1024850A)","Biological: Infanrix™-IPV/Hib"]}],"interventions":[{"name":"GSK Biologicals´ Pneumococcal Conjugate Vaccine (GSK1024850A)","otherNames":[]},{"name":"Infanrix™-IPV/Hib","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol should be enrolled in the study.\n* A male or female between, and including, 16-18 months of age at the time of the booster vaccination.\n* A male or female who previously participated in study 107737 and received three doses of pneumococcal conjugate vaccine.\n* Written informed consent obtained from the parent or guardian of the subject.\n* Free of obvious health problems as established by medical history and clinical examination before entering into the study.\n\nExclusion Criteria:\n\n* Concurrently participating in another clinical study, at any time during the study period (active phase and extended safety follow-up), in which the subject has been or will be exposed to an investigational or a non-investigational product.\n* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccines within 30 days preceding the booster dose of study vaccines, or planned use during the study period (active phase and 5 months extended safety follow-up).\n* Chronic administration of immunosuppressants or other immune-modifying drugs within 6 months prior to the booster dose of study vaccine.\n* Planned administration/administration of a vaccine not foreseen by the study protocol, during the period starting from one month (30 days) before the booster dose of study vaccines (Visit 1) and up to the follow-up visit (Visit 2).\n* Previous vaccination against diphtheria, tetanus, pertussis, polio, hepatitis B, Haemophilus influenzae type b and/or Streptococcus pneumoniae other than the study vaccines from study 107737\n* History of or intercurrent diphtheria, tetanus, hepatitis B, pertussis, polio, Haemophilus influenzae type b disease.\n* History of allergic disease or reactions likely to be exacerbated by any component of the vaccines.\n* History of seizures or progressive neurological disease\n* Acute disease at the time of enrolment.\n* Febrile illness defined as oral, axillary or tympanic temperature \\< 37.5°C / rectal temperature \\< 38°C. A temperature greater than or equal to these cut-offs warrants deferral of the vaccination pending recovery of the subject.\n* Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination.\n* A family history of congenital or hereditary immunodeficiency.\n* Major congenital defects or serious chronic illness.\n* Administration of immunoglobulins, with the exception of monoclonal antibodies against RSV, and/or any blood products within three months preceding the booster dose of study vaccines or planned administration during the active phase of the study.","healthyVolunteers":true,"sex":"ALL","minimumAge":"16 Months","maximumAge":"18 Months","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Subjects Reporting Fever With Rectal Temperature Above (>) 39.0 Degrees Celsius (°C)","description":"Fever was measured as rectal temperature. Assessment of occurrences of fever \\> 39.0 °C was performed within 4-days (Day 0-3) after booster vaccination of Synflorix™ and Infanrix™-IPV/Hib vaccine.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Any and Grade 3 Solicited Local Symptoms","description":"Solicited local symptoms assessed included pain, redness and swelling. Grade 3 pain was defined as crying when limb was moved/spontaneously painful. Grade 3 swelling/redness was defined as swelling/redness larger than (\\>) 30 millimeters (mm). \"Any\" is defined as incidence of the specified symptom regardless of intensity.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null},{"groupId":"OG001","value":"67","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35","spread":null},{"groupId":"OG001","value":"65","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"55","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Any and Grade 3 Solicited General Symptoms","description":"Solicited general symptoms assessed included drowsiness, fever (defined as rectal temperature ≥ 38.0°C), irritability, and loss of appetite. Grade 3 drowsiness was defined as drowsiness which prevented normal everyday activities. Grade 3 fever was defined as fever (rectal temperature) above (\\>) 40.0 degree Celsius (°C). Grade 3 irritability was defined as crying that could not be comforted/preventing normal activity. Grade 3 loss of appetite was defined as the subject not eating at all. \"Any\" is defined as incidence of the specified symptom regardless of intensity or relationship to study vaccination.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"39","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"49","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Unsolicited Adverse Events (AEs)","description":"An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. \"Any\" is defined as incidence of an unsolicited AE regardless of intensity or relationship to study vaccination.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"24","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Serious Adverse Events (SAEs)","description":"Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Serious Adverse Events (SAEs)","description":"Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Seropositive Subjects for Anti-pneumococcal Serotypes","description":"A seropositive subject was defined as a subject who had the anti-pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C , 19F and 23F concentrations greater than or equal to (≥) the cut-off value of 0.05 micrograms per milliliter (μg/mL).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null},{"groupId":"OG001","value":"56","spread":null},{"groupId":"OG002","value":"111","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"66","spread":null},{"groupId":"OG002","value":"119","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":null},{"groupId":"OG001","value":"68","spread":null},{"groupId":"OG002","value":"120","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"66","spread":null},{"groupId":"OG002","value":"119","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"66","spread":null},{"groupId":"OG002","value":"122","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"66","spread":null},{"groupId":"OG002","value":"119","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"66","spread":null},{"groupId":"OG002","value":"119","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null},{"groupId":"OG001","value":"65","spread":null},{"groupId":"OG002","value":"119","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null},{"groupId":"OG001","value":"65","spread":null},{"groupId":"OG002","value":"123","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"66","spread":null},{"groupId":"OG002","value":"118","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"69","spread":null},{"groupId":"OG002","value":"123","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"66","spread":null},{"groupId":"OG002","value":"119","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"68","spread":null},{"groupId":"OG002","value":"121","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"66","spread":null},{"groupId":"OG002","value":"119","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"68","spread":null},{"groupId":"OG002","value":"123","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"66","spread":null},{"groupId":"OG002","value":"118","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"68","spread":null},{"groupId":"OG002","value":"125","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"66","spread":null},{"groupId":"OG002","value":"119","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"68","spread":null},{"groupId":"OG002","value":"122","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"66","spread":null},{"groupId":"OG002","value":"118","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Seroprotected Subjects Against Anti-pneumococcal Serotypes","description":"A seroprotected subjects was defined as a subject who had anti-pneumococcal serotypes antibody concentrations greater than or equal to (≥) the threshold value of 0.20 micrograms per milliliter (μg/mL). The anti-pneumococcal serotypes assessed were 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"28","spread":null},{"groupId":"OG002","value":"53","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"66","spread":null},{"groupId":"OG002","value":"118","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"40","spread":null},{"groupId":"OG002","value":"82","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"66","spread":null},{"groupId":"OG002","value":"119","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"43","spread":null},{"groupId":"OG002","value":"105","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"66","spread":null},{"groupId":"OG002","value":"119","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"41","spread":null},{"groupId":"OG002","value":"99","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null},{"groupId":"OG001","value":"65","spread":null},{"groupId":"OG002","value":"119","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"56","spread":null},{"groupId":"OG002","value":"115","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"66","spread":null},{"groupId":"OG002","value":"118","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null},{"groupId":"OG001","value":"59","spread":null},{"groupId":"OG002","value":"115","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"66","spread":null},{"groupId":"OG002","value":"119","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"55","spread":null},{"groupId":"OG002","value":"105","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"66","spread":null},{"groupId":"OG002","value":"119","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"60","spread":null},{"groupId":"OG002","value":"106","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"66","spread":null},{"groupId":"OG002","value":"118","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null},{"groupId":"OG001","value":"66","spread":null},{"groupId":"OG002","value":"120","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"66","spread":null},{"groupId":"OG002","value":"119","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"45","spread":null},{"groupId":"OG002","value":"99","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"66","spread":null},{"groupId":"OG002","value":"118","spread":null}]}]}]},{"type":"SECONDARY","title":"Antibody Concentrations Against Pneumococcal Serotypes","description":"Seropositivity status was defined as the anti-pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F antibody concentrations greater than or equal to (≥) the cut-off value of 0.05 micrograms per milliliter (µg/mL). Antibody concentrations were measured by 22F enzyme-linked immunosorbent assay (ELISA), presented as geometric mean concentrations (GMCs).","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.15","spread":null},{"groupId":"OG001","value":"0.14","spread":null},{"groupId":"OG002","value":"0.17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.57","spread":null},{"groupId":"OG001","value":"1.74","spread":null},{"groupId":"OG002","value":"1.98","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.25","spread":null},{"groupId":"OG001","value":"0.24","spread":null},{"groupId":"OG002","value":"0.30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.98","spread":null},{"groupId":"OG001","value":"3.67","spread":null},{"groupId":"OG002","value":"4.23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.24","spread":null},{"groupId":"OG001","value":"0.27","spread":null},{"groupId":"OG002","value":"0.40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.84","spread":null},{"groupId":"OG001","value":"2.38","spread":null},{"groupId":"OG002","value":"2.58","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.28","spread":null},{"groupId":"OG001","value":"0.30","spread":null},{"groupId":"OG002","value":"0.37","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.44","spread":null},{"groupId":"OG001","value":"2.46","spread":null},{"groupId":"OG002","value":"2.67","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.42","spread":null},{"groupId":"OG001","value":"0.46","spread":null},{"groupId":"OG002","value":"0.66","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.11","spread":null},{"groupId":"OG001","value":"4.16","spread":null},{"groupId":"OG002","value":"3.93","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.51","spread":null},{"groupId":"OG001","value":"0.42","spread":null},{"groupId":"OG002","value":"0.59","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.87","spread":null},{"groupId":"OG001","value":"3.47","spread":null},{"groupId":"OG002","value":"4.17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.78","spread":null},{"groupId":"OG001","value":"0.48","spread":null},{"groupId":"OG002","value":"0.68","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.88","spread":null},{"groupId":"OG001","value":"5.14","spread":null},{"groupId":"OG002","value":"5.98","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.58","spread":null},{"groupId":"OG001","value":"0.56","spread":null},{"groupId":"OG002","value":"0.60","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.51","spread":null},{"groupId":"OG001","value":"13.20","spread":null},{"groupId":"OG002","value":"12.38","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.86","spread":null},{"groupId":"OG001","value":"1.07","spread":null},{"groupId":"OG002","value":"1.27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.83","spread":null},{"groupId":"OG001","value":"9.78","spread":null},{"groupId":"OG002","value":"9.72","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.27","spread":null},{"groupId":"OG001","value":"0.30","spread":null},{"groupId":"OG002","value":"0.42","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.70","spread":null},{"groupId":"OG001","value":"3.45","spread":null},{"groupId":"OG002","value":"3.30","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Seropositive Subjects for Pneumococcal Cross-reactive Serotypes 6A and 19A","description":"A seropositive subject was defined as a subject who had the anti-pneumococcal serotypes 6A and 19A concentrations greater than or equal to (≥) the cut-off value of 0.05 micrograms per milliliter (μg/mL).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"51","spread":null},{"groupId":"OG002","value":"98","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"63","spread":null},{"groupId":"OG002","value":"115","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"49","spread":null},{"groupId":"OG002","value":"95","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":null},{"groupId":"OG001","value":"63","spread":null},{"groupId":"OG002","value":"113","spread":null}]}]}]},{"type":"SECONDARY","title":"Antibody Concentrations Against Pneumococcal Cross-reactive Serotypes 6A and 19A","description":"Seropositivity status was defined as the anti-pneumococcal cross-reactive serotypes 6A and 19A antibody concentrations greater than or equal to (≥) the cut-off value of 0.05 micrograms per milliliter (µg/mL). Antibody concentrations were measured by 22F enzyme-linked immunosorbent assay (ELISA), presented as geometric mean concentrations (GMCs).","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.12","spread":null},{"groupId":"OG001","value":"0.12","spread":null},{"groupId":"OG002","value":"0.14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.70","spread":null},{"groupId":"OG001","value":"0.77","spread":null},{"groupId":"OG002","value":"0.79","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.14","spread":null},{"groupId":"OG001","value":"0.15","spread":null},{"groupId":"OG002","value":"0.16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.65","spread":null},{"groupId":"OG001","value":"0.93","spread":null},{"groupId":"OG002","value":"1.10","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Seropositive Subjects for Protein D Antibodies (Anti-PD)","description":"A seropositive subject was defined as a subject who had anti-PD concentration greater than or equal to (≥) the value of 100 ELISA units per milliliter (EL.U/mL).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null},{"groupId":"OG001","value":"58","spread":null},{"groupId":"OG002","value":"114","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"66","spread":null},{"groupId":"OG002","value":"117","spread":null}]}]}]},{"type":"SECONDARY","title":"Antibody Concentrations Against Protein D (Anti-PD)","description":"Seropositivity status was defined as the anti-protein D (Anti-PD) antibody concentrations greater than or equal to (≥) 100 ELISA units per milliliter (EL.U/mL). Antibody concentrations were measured by enzyme-linked immunosorbent assay (ELISA), presented as geometric mean concentrations (GMCs).","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"478.3","spread":null},{"groupId":"OG001","value":"340.0","spread":null},{"groupId":"OG002","value":"383.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1892.9","spread":null},{"groupId":"OG001","value":"1576.5","spread":null},{"groupId":"OG002","value":"1533.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Seroprotected Subjects Against Anti-diphtheria (Anti-DT) and Anti-tetanus Toxoids (Anti-TT)","description":"A seroprotected subject was defined as a subject who had anti-DT and anti-TT concentrations greater than or equal to (≥) the value of 0.1 international units per milliliter (IU/mL).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"27","spread":null},{"groupId":"OG002","value":"51","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"34","spread":null},{"groupId":"OG002","value":"60","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"32","spread":null},{"groupId":"OG002","value":"59","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"34","spread":null},{"groupId":"OG002","value":"60","spread":null}]}]}]},{"type":"SECONDARY","title":"Antibody Concentrations Against Anti-diphtheria (Anti-DT) and Anti-tetanus Toxoids (Anti-TT)","description":"Seropositivity status was defined as the anti-diphtheria toxoid (Anti-DT) and anti-tetanus toxoid (Anti-TT) antibody concentrations greater than or equal to (≥) 0.1 international units per milliliter (IU/mL). Antibody concentrations were measured by enzyme-linked immunosorbent assay (ELISA), presented as geometric mean concentrations (GMCs).","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.381","spread":null},{"groupId":"OG001","value":"0.674","spread":null},{"groupId":"OG002","value":"0.481","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.252","spread":null},{"groupId":"OG001","value":"9.982","spread":null},{"groupId":"OG002","value":"6.730","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.821","spread":null},{"groupId":"OG001","value":"0.726","spread":null},{"groupId":"OG002","value":"0.918","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.374","spread":null},{"groupId":"OG001","value":"14.392","spread":null},{"groupId":"OG002","value":"13.026","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Seroprotected Subjects Against Anti-polyribosyl-ribitol Phosphate (Anti-PRP)","description":"A seroprotected subject was defined as a subject who had anti-PRP concentrations greater than or equal to (≥) the value of 0.15 micrograms per milliliter (µg /mL).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"26","spread":null},{"groupId":"OG002","value":"50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"34","spread":null},{"groupId":"OG002","value":"59","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Anti-polyribosyl-ribitol Phosphate (Anti-PRP) Antibody Concentration ≥ 1.0 µg/mL","description":"The concentration of anti-polyribosyl-ribitol phosphate (Anti-PRP) antibody assessed was greater than or equal to (≥) the value of 1.0 micrograms per milliliter (µg /mL).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"34","spread":null},{"groupId":"OG002","value":"59","spread":null}]}]}]},{"type":"SECONDARY","title":"Antibody Concentrations Against Anti-polyribosyl-ribitol-phosphate (Anti-PRP)","description":"Seropositivity status was defined as the anti-polyribosyl-ribitol-phosphate (Anti-PRP) antibody concentrations greater than or equal to (≥) 0.15 micrograms per milliliter (µg /mL) and ≥ 1.0 µg/mL. Antibody concentrations were measured by enzyme-linked immunosorbent assay (ELISA), presented as geometric mean concentrations (GMCs).","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.376","spread":null},{"groupId":"OG001","value":"0.509","spread":null},{"groupId":"OG002","value":"0.577","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.731","spread":null},{"groupId":"OG001","value":"36.902","spread":null},{"groupId":"OG002","value":"38.713","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Seropositive Subjects for Anti-pertussis Toxoid (Anti-PT), Anti- Filamentous Haemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN)","description":"A seropositive subject was defined as a subject who had anti-PT, anti-FHA and anti-PRN concentrations greater than or equal to (≥) the value of 5 ELISA units per milliliter (EL.U/mL).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"11","spread":null},{"groupId":"OG002","value":"30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"34","spread":null},{"groupId":"OG002","value":"59","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"24","spread":null},{"groupId":"OG002","value":"43","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"34","spread":null},{"groupId":"OG002","value":"59","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"28","spread":null},{"groupId":"OG002","value":"47","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"34","spread":null},{"groupId":"OG002","value":"60","spread":null}]}]}]},{"type":"SECONDARY","title":"Antibody Concentrations Against Anti-pertussis Toxoid (Anti-PT), Anti-filamentous Haemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN)","description":"Seropositivity status was defined as the anti-pertussis toxoid (Anti-PT), anti-filamentous haemagglutinin (Anti-FHA) and anti-pertactin (Anti-PRN) antibody concentrations greater than or equal to (≥) 5 ELISA units per milliliter (EL.U /mL). Antibody concentrations were measured by enzyme-linked immunosorbent assay (ELISA), presented as geometric mean concentrations (GMCs).","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.7","spread":null},{"groupId":"OG001","value":"3.8","spread":null},{"groupId":"OG002","value":"5.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.4","spread":null},{"groupId":"OG001","value":"32.7","spread":null},{"groupId":"OG002","value":"45.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.4","spread":null},{"groupId":"OG001","value":"13.7","spread":null},{"groupId":"OG002","value":"17.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"250.3","spread":null},{"groupId":"OG001","value":"275.3","spread":null},{"groupId":"OG002","value":"229.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.7","spread":null},{"groupId":"OG001","value":"10.3","spread":null},{"groupId":"OG002","value":"11.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"259.7","spread":null},{"groupId":"OG001","value":"286.5","spread":null},{"groupId":"OG002","value":"264.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Vaccine Response for Anti-PT, Anti-FHA and Anti-PRN Antibodies","description":"Vaccine response was defined as antibody concentrations ≥ 5 EL.U/mL at post-booster, for initially seronegative subjects (S-) (with concentrations \\< 5 EL.U/mL) and for initially seropositive subjects (S+) (with concentrations ≥ 5 EL.U/mL), antibody concentrations at post-booster ≥ 2 fold the pre-vaccination antibody concentration.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"21","spread":null},{"groupId":"OG002","value":"27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"11","spread":null},{"groupId":"OG002","value":"24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"24","spread":null},{"groupId":"OG002","value":"37","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"28","spread":null},{"groupId":"OG002","value":"44","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Seroprotected Subjects Against Anti-polio Type 1, 2 and 3 (Anti-Polio 1, 2 and 3)","description":"A seroprotected subject was defined as a subject who had anti-polio types 1, 2 and 3 titers greater than or equal to (≥) the value of 8.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"22","spread":null},{"groupId":"OG002","value":"49","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"26","spread":null},{"groupId":"OG002","value":"47","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"23","spread":null},{"groupId":"OG002","value":"51","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"20","spread":null}]}]}]},{"type":"SECONDARY","title":"Antibody Titers Against Anti-polio Type 1, 2 and 3","description":"Seroprotection status was defined as the anti-polio type 1, anti-polio type 2 and anti-polio type 3 antibody titers greater than or equal to (≥) the cut-off value of 8, presented as geometric mean titers (GMTs).","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52.3","spread":null},{"groupId":"OG001","value":"34.8","spread":null},{"groupId":"OG002","value":"54.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"512.0","spread":null},{"groupId":"OG001","value":"1386.7","spread":null},{"groupId":"OG002","value":"1327.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"65.2","spread":null},{"groupId":"OG001","value":"47.3","spread":null},{"groupId":"OG002","value":"50.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1290.1","spread":null},{"groupId":"OG001","value":"2048.0","spread":null},{"groupId":"OG002","value":"1116.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.0","spread":null},{"groupId":"OG001","value":"31.3","spread":null},{"groupId":"OG002","value":"84.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"574.7","spread":null},{"groupId":"OG001","value":"1448.1","spread":null},{"groupId":"OG002","value":"1692.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Antibody Concentrations Against Anti-hepatitis B Surface Antigen (HBs)","description":"Seroprotection status was defined as the Anti-HBs antibody concentrations greater than or equal to (≥) 10 milli international units per milliliter (mIU/mL), presented as geometric mean concentrations (GMCs).","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.9","spread":null},{"groupId":"OG001","value":"117.2","spread":null},{"groupId":"OG002","value":"37.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Seropositive Subjects for Opsonophagocytic Activity (OPA) Against Pneumococcal Serotypes","description":"A seropositive subject was defines as a subject with opsonophagocytic activity cut-off value greater than or equal to (≥) the value of 8. The vaccine pneumococcal serotypes investigated were 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"49","spread":null},{"groupId":"OG002","value":"93","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35","spread":null},{"groupId":"OG001","value":"55","spread":null},{"groupId":"OG002","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null},{"groupId":"OG001","value":"48","spread":null},{"groupId":"OG002","value":"92","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":null},{"groupId":"OG001","value":"49","spread":null},{"groupId":"OG002","value":"92","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null},{"groupId":"OG001","value":"49","spread":null},{"groupId":"OG002","value":"99","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null},{"groupId":"OG001","value":"47","spread":null},{"groupId":"OG002","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"52","spread":null},{"groupId":"OG002","value":"99","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null},{"groupId":"OG001","value":"50","spread":null},{"groupId":"OG002","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"51","spread":null},{"groupId":"OG002","value":"96","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null},{"groupId":"OG001","value":"54","spread":null},{"groupId":"OG002","value":"99","spread":null}]}]}]},{"type":"SECONDARY","title":"Opsonophagocytic Activity (OPA) Against Pneumococcal Serotypes","description":"Seropositivity status was defined as the opsonophagocytic activity (OPA) against pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F, with a cut-off value greater than or equal to (≥) 8, presented as geometric mean titers (GMTs).","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"125","spread":null},{"groupId":"OG001","value":"143.6","spread":null},{"groupId":"OG002","value":"170.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"971.8","spread":null},{"groupId":"OG001","value":"1307.2","spread":null},{"groupId":"OG002","value":"1479.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69.2","spread":null},{"groupId":"OG001","value":"120.0","spread":null},{"groupId":"OG002","value":"176.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"659.0","spread":null},{"groupId":"OG001","value":"459.1","spread":null},{"groupId":"OG002","value":"635.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6008.9","spread":null},{"groupId":"OG001","value":"4851.1","spread":null},{"groupId":"OG002","value":"4372.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1666.4","spread":null},{"groupId":"OG001","value":"2192.5","spread":null},{"groupId":"OG002","value":"1798.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1489.5","spread":null},{"groupId":"OG001","value":"1895.3","spread":null},{"groupId":"OG002","value":"1342.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1656.0","spread":null},{"groupId":"OG001","value":"1672.4","spread":null},{"groupId":"OG002","value":"1561.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"379.3","spread":null},{"groupId":"OG001","value":"486.3","spread":null},{"groupId":"OG002","value":"626.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2881.8","spread":null},{"groupId":"OG001","value":"2510.2","spread":null},{"groupId":"OG002","value":"3208.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Seropositive Subjects for Opsonophagocytic Activity (OPA) Against Pneumococcal Cross-reactive Serotypes 6A and 19A","description":"A seropositive subject was defined as a subject with opsonophagocytic activity against pneumococcal cross-reactive serotypes 6A and 19A greater than or equal to (≥) the cut-off value of 8.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"45","spread":null},{"groupId":"OG002","value":"79","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"30","spread":null},{"groupId":"OG002","value":"56","spread":null}]}]}]},{"type":"SECONDARY","title":"Opsonophagocytic Activity (OPA) Against Pneumococcal Cross-reactive Serotypes 6A and 19A","description":"Seropositivity status was defined as the opsonophagocytic activity (OPA) against pneumococcal cross-reactive serotypes 6A and 19A, with a cut-off value greater than or equal to (≥) 8, presented as geometric mean titers (GMTs).","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"270.6","spread":null},{"groupId":"OG001","value":"218.2","spread":null},{"groupId":"OG002","value":"207.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.9","spread":null},{"groupId":"OG001","value":"41.4","spread":null},{"groupId":"OG002","value":"51.7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":116},"commonTop":["Pain","Redness","Irritability","Swelling","Fever (rectal temperature measurement)"]}}}